Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations [Yahoo! Finance]
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target lowered by analysts at Needham & Company LLC from $6.00 to $4.00. They now have a "buy" rating on the stock.